- Previous Close
9.48 - Open
9.12 - Bid 9.03 x 100
- Ask 9.16 x 100
- Day's Range
8.69 - 9.35 - 52 Week Range
8.69 - 45.00 - Volume
579,450 - Avg. Volume
421,170 - Market Cap (intraday)
247.061M - Beta (5Y Monthly) 3.41
- PE Ratio (TTM)
-- - EPS (TTM)
-3.00 - Earnings Date May 6, 2025 - May 12, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
73.10
Arcturus Therapeutics Holdings Inc. engages in the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms includes LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate that is in phase 2 clinical trial for cystic fibrosis. Its product pipeline includes KOSTAIVE for the treatment of covid 19; ARCT-2138 (LUNAR-FLU), which is in phase 1 clinical trial for the treatment of seasonal influenza; ARCT-2304 (LUNAR-H5N1) that is in phase 1 clinical trial for the treatment of Pandemic Influenza; ARCT-2301 for bivalent: ancestral/omicron which is in Phase 3 clinical trial; and ARCT-2303 for monovalent that is in Phase 3 clinical trial. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.
arcturusrx.comRecent News: ARCT
View More
Performance Overview: ARCT
Trailing total returns as of 4/4/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ARCT
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ARCT
View MoreValuation Measures
Market Cap
246.52M
Enterprise Value
38.04M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
1.77
Price/Book (mrq)
1.02
Enterprise Value/Revenue
0.27
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-53.14%
Return on Assets (ttm)
-15.46%
Return on Equity (ttm)
-31.16%
Revenue (ttm)
152.31M
Net Income Avi to Common (ttm)
-80.94M
Diluted EPS (ttm)
-3.00
Balance Sheet and Cash Flow
Total Cash (mrq)
237.03M
Total Debt/Equity (mrq)
11.85%
Levered Free Cash Flow (ttm)
-9.02M
Research Analysis: ARCT
View MoreResearch Reports: ARCT
View MoreDaily – Vickers Top Buyers & Sellers for 06/17/2024
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
Daily – Vickers Top Buyers & Sellers for 11/29/2022
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
Daily – Vickers Top Buyers & Sellers for 08/13/2021
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.